Rein Therapeutics (NASDAQ:RNTX) Rating Lowered to “Sell” at Wall Street Zen

Rein Therapeutics (NASDAQ:RNTX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Several other research firms have also recently commented on RNTX. Loop Capital set a $6.00 target price on Rein Therapeutics in a research note on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Brookline Capital Management upgraded shares of Rein Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 3rd. Finally, HC Wainwright started coverage on shares of Rein Therapeutics in a research report on Monday, September 22nd. They set a “buy” rating and a $10.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Stock Up 0.6%

RNTX opened at $1.55 on Friday. Rein Therapeutics has a 52 week low of $1.04 and a 52 week high of $3.50. The business has a fifty day simple moving average of $1.41 and a 200-day simple moving average of $1.41. The firm has a market cap of $40.75 million, a P/E ratio of -0.59 and a beta of 1.27.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. Sell-side analysts expect that Rein Therapeutics will post -1.56 earnings per share for the current year.

Insider Activity at Rein Therapeutics

In other Rein Therapeutics news, major shareholder Voss Capital, Lp purchased 178,392 shares of the stock in a transaction on Tuesday, October 28th. The shares were purchased at an average price of $1.39 per share, with a total value of $247,964.88. Following the acquisition, the insider directly owned 500,000 shares in the company, valued at approximately $695,000. The trade was a 55.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have acquired 410,233 shares of company stock worth $550,563. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Rein Therapeutics

A number of hedge funds have recently made changes to their positions in RNTX. Gleason Group Inc. bought a new stake in shares of Rein Therapeutics in the third quarter worth about $26,000. Blair William & Co. IL purchased a new stake in Rein Therapeutics in the 2nd quarter worth approximately $33,000. Susquehanna International Group LLP bought a new stake in shares of Rein Therapeutics in the 3rd quarter worth approximately $35,000. Meridian Wealth Advisors LLC bought a new stake in shares of Rein Therapeutics in the 2nd quarter worth approximately $40,000. Finally, Exencial Wealth Advisors LLC purchased a new position in shares of Rein Therapeutics during the second quarter valued at approximately $43,000. 90.89% of the stock is currently owned by institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.